Choosing the Right Excipients for the Right Job
When it comes to formulation, many choices should be carefully considered – and regulators expect excipient selection to be justified.
Rob Harris |
sponsored by BASF
The average timelines and costs of bringing a new drug to market vary depending on who you speak with, but are generally in the range of 10 years and over $2 billion, respectively. The broad hurdles of drug development are considered, but a topic that receives far less attention is formulation, including the choice of excipients.
The right excipients can reduce manufacturing costs, improve shelf life and stability, and enhance the patient experience. The competitive contract development and manufacturing landscape has given rise to CDMOs who hold impressive knowledge and know-how in terms of applying good scientific common sense in selecting the most appropriate excipients for the job at hand. Here, we speak with Rob Harris, Chief Technical Officer, Oral Drug Delivery, Catalent, UK, to find out more about the latest trends and drivers in the excipient field.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.